News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
685,572 Results
Type
Article (42310)
Company Profile (280)
Press Release (642982)
Section
Business (204723)
Career Advice (1990)
Deals (35478)
Drug Delivery (80)
Drug Development (81153)
Employer Resources (168)
FDA (16076)
Job Trends (14872)
News (345638)
Policy (32649)
Tag
Academia (2609)
Africa (735)
Alliances (49417)
Alzheimer's disease (1141)
Approvals (16010)
Arizona (170)
Artificial intelligence (65)
Asia (37227)
Australia (6098)
Bankruptcy (353)
Best Places to Work (11316)
Biosimilars (62)
Biotechnology (200)
C2C Services and Suppliers (79221)
California (1666)
Canada (861)
Cancer (340)
Career advice (1657)
Cell therapy (104)
China (121)
Clinical research (63331)
Collaboration (117)
Colorado (65)
Compensation (61)
Connecticut (65)
COVID-19 (2515)
Cystic fibrosis (72)
Data (169)
Diabetes (70)
Diagnostics (6020)
Drug pricing (63)
Earnings (83909)
Employer resources (143)
Europe (80043)
Events (108408)
Executive appointments (113)
FDA (16260)
Florida (233)
Funding (110)
Gene therapy (85)
GLP-1 (506)
Government (4315)
Healthcare (18697)
Hotbed/Location (483685)
Illinois (241)
Indiana (136)
Infectious disease (2539)
Inflammatory bowel disease (87)
Interviews (309)
IPO (16235)
Job creations (3642)
Job search strategy (1422)
Kansas (93)
Layoffs (399)
Legal (7880)
Lung cancer (74)
Manufacturing (74)
Maryland (358)
Massachusetts (1385)
Medical device (13030)
Medtech (13033)
Mergers & acquisitions (19066)
Metabolic disorders (226)
Michigan (118)
Minnesota (206)
Neuroscience (1267)
New Jersey (502)
New York (522)
NextGen Class of 2024 (6549)
Non-profit (4518)
North Carolina (581)
Northern California (749)
Obesity (140)
Ohio (98)
Opinion (173)
Patents (65)
Pennsylvania (541)
People (56148)
Pharmaceutical (60)
Phase I (19667)
Phase II (27880)
Phase III (20829)
Pipeline (99)
Postmarket research (2567)
Preclinical (8418)
Press Release (67)
Rare diseases (119)
Real estate (5919)
Recruiting (63)
Regulatory (21322)
Research institute (2401)
Resumes & cover letters (348)
South America (1106)
Southern California (667)
Startups (3608)
Texas (203)
United States (7781)
Vaccines (460)
Washington State (242)
Weight loss (121)
Date
Today (6)
Last 7 days (585)
Last 30 days (2047)
Last 365 days (37434)
2024 (25210)
2023 (40317)
2022 (51526)
2021 (56040)
2020 (54401)
2019 (46871)
2018 (35300)
2017 (32460)
2016 (31917)
2015 (37926)
2014 (31652)
2013 (26839)
2012 (29017)
2011 (29667)
2010 (27744)
685,572 Results for "atossa genetics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Societal CDMO Enters Agreement With Atossa Therapeutics to Provide Clinical Trial Services (CTS) for Innovative Selective Estrogen Receptor Modulator
Societal CDMO, Inc. today announced that it has been selected by Atossa Therapeutics (Nasdaq: ATOS ) to provide a range of its Clinical Trial Services (CTS) offerings focused on Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen.
May 23, 2023
·
5 min read
Business
Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial
Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative™ (“Quantum Leap”) today announced that six patients have been dosed with Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, in the ongoing Phase 2 I-SPY 2 clinical trial.
June 28, 2023
·
6 min read
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Genetics in Medicine, an official journal of the American College of Medical Genetics and Genomics (ACMG), published a new study validating RiskScore®, Myriad’s breast cancer risk assessment tool integrated into its MyRisk® Hereditary Cancer Test.
June 3, 2024
·
4 min read
BioMidwest
Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced the addition of a new Universal Plus Panel to its Foresight® Carrier Screen.
June 4, 2024
·
2 min read
BioForest
Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial
Atossa Therapeutics, Inc. (Nasdaq: ATOS) and Quantum Leap Healthcare Collaborative™ today announce that Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, will be evaluated in a new study arm of the ongoing I-SPY 2 clinical trial.
March 21, 2023
·
8 min read
Biotech Beach
Ionis to present at TD Cowen Genetic Medicines & RNA Summit
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a fireside chat at the virtual TD Cowen Genetic Medicines & RNA Summit on Thursday, June 20, 2024.
June 17, 2024
·
1 min read
BioForest
3X4 Genetics Selected as Partner for Preeminent Cancer Research and Treatment Nonprofit, The Metabolic Terrain Institute of Health
3X4 Genetics, leader in the field of genetics-based health, announced a partnership with The Metabolic Terrain Institute of Health to serve as the innovative nonprofit’s genetics provider.
June 25, 2024
·
3 min read
Gene Therapy
Gene Therapies Break Through Against Genetic Hearing Loss in Children
Regeneron, Akouos and Mass Eye and Ear are testing therapies that can reverse genetic protein deficiency to restore hearing, with promising early results.
August 19, 2024
·
5 min read
·
Jill Drachenberg
BioMidwest
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, and its collaborators will share data from seven studies at the 2024 ASCO Annual Meeting.
May 23, 2024
·
7 min read
Rare Diseases
Biopharma Entrepreneurs Make Business Case for Personalized Genetic Medicines
Experts say the time is now to develop and provide widespread access to genetic medicines for the rarest diseases. What’s more, they say it is a moral imperative.
August 7, 2024
·
6 min read
·
Heather McKenzie
1 of 68,558
Next